News from alimera sciences, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 17, 2014, 11:45 ET

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization...

Nov 12, 2014, 07:30 ET

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization...

Nov 06, 2014, 16:13 ET

Alimera Sciences Reports Third Quarter 2014 Financial Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization...

Oct 23, 2014, 16:15 ET

Alimera Sciences to Release Third Quarter 2014 Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization...

Oct 09, 2014, 08:30 ET

Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of...

Sep 30, 2014, 13:50 ET

Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization...

Sep 29, 2014, 07:30 ET

Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema

Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of...

Sep 26, 2014, 16:15 ET

Alimera Sciences Receives FDA Approval For ILUVIEN®, The First Long-Term Treatment For Diabetic Macular Edema

Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of...

Sep 03, 2014, 07:30 ET

Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of...

Aug 07, 2014, 16:22 ET

Alimera Sciences Reports Second Quarter 2014 Financial Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

Jul 31, 2014, 16:01 ET

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Denmark For The Treatment Of Chronic Diabetic Macular Edema

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

Jul 28, 2014, 16:01 ET

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Norway For The Treatment Of Chronic Diabetic Macular Edema

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

Jul 24, 2014, 14:22 ET

Alimera Sciences To Release Second Quarter 2014 Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and...

Jun 30, 2014, 07:30 ET

Alimera Sciences' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries

 Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

Jun 23, 2014, 23:19 ET

Alimera Sciences riceve l'autorizzazione all'immissione in commercio di ILUVIEN®, il suo farmaco per il trattamento dell'edema maculare diabetico cronico

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), una società biofarmaceutica specializzata nella ricerca, nello sviluppo e nella...

Jun 23, 2014, 07:00 ET

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Italy For The Treatment Of Chronic Diabetic Macular Edema

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

May 27, 2014, 16:05 ET

Alimera Sciences To Present At Jefferies Healthcare Conference

 Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and...

May 08, 2014, 16:05 ET

Alimera Sciences Reports First Quarter 2014 Financial Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...

May 01, 2014, 07:00 ET

Alimera Sciences To Release First Quarter 2014 Results

 Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and...

Apr 28, 2014, 07:00 ET

Alimera Sciences Signs Specialised Therapeutics Australia (STA) As Exclusive ILUVIEN® Distributor For Australia, New Zealand

 Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and...